p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis

Gut

Volumn 38, Issue 2, 1996, Pages 265-268

  Rizzi, P M ^a   Ryder, S D ^a   Portmann, B ^a   Ramage, J K ^a   Naoumov, N V ^a   Williams, Roger ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; p53; Primary sclerosing cholangitis

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TUMOR CELL;

EID: 0030061061     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.2.265     Document Type: Article

References (22)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
2. Lane DP. A death in the life of p53. Nature 1993; 362: 786-7.
3. Gammon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602
4. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-8.
5. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
6. Kar S, Jaffe R, Carr BI. Mutations at codon of p53 gene in human hepatoblastoma. Hepatology 1993; 18: 566-9.
7. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumours. Am J Pathol 1992; 140: 145-53.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
9. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, Larusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21-5.
10. Ramage JK, Donaghy A, Farrant M, Iorns R, Williams R. Serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-9.
11. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993; 23: 377-9.
12. Shi SR, Key ME, Lalra KL. Antigen retrival in formalin-fixed, paraffin embedded tissues: an enhanced method for immunohistochemical staining based on microwave over heating of tissue sections. J Histochem Cytochem 1991; 39: 741.
13. Bressac B, Gavin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human HCC. Proc Natl Acad Sci USA 1990; 87: 1973-7.
14. Vauthhey JN, Blumgart LH. Recent advances in the management of cholangiocarcinoma. Semin Liv Dis 1994; 14: 109-15.
15. Kinzler KW, Volgstein B. Clinical implications of basic research. Cancer therapy meets p53. N Engl J Med 1994; 331: 49-50.
16. Harris CC, Hollstein M. Clinical implications of the p53 tumour suppressor gene. N Engl J Med 1993; 329: 1318-27.
17. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
18. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-62.
19. Terada T, Shimizu K, Izumi R, Nakanuma Y. p53 expression in formalin-fixed, paraffin embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 1994; 7: 249-52.
20. Baast IO, Mulder JWR, Offerhaust GJA, Vogelstain B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasm. J Pathol 1994; 172: 5-12.
21. Hall PA, Lane DP. p55 in tumour pathology: Can we trust immunohistochemistry? Revisited. J Pathol 1994; 172: 1-4.
22. Nakajima T, Kondo Y. Well differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol 1989; 13: 569-73.